ISTITUTI FISIOTERAPICI OSPITALIERI

Their core work

IFO is a Rome-based hospital group that includes the Regina Elena National Cancer Institute, one of Italy's leading oncology centres. Their H2020 involvement focuses on advancing cancer diagnostics — from ultrasensitive biosensor platforms for early detection to next-generation sequencing and liquid biopsies for precision oncology. They bring clinical expertise and patient access to EU research consortia, serving as the bridge between laboratory diagnostic innovations and real-world clinical validation.

What they specialise in

How they've shifted over time

IFO's trajectory shows a clear shift from hardware-focused diagnostic tools toward data-driven genomic diagnostics. Their early involvement (2015-2018, ULTRAPLACAD) centred on plasmonic biosensor devices for early cancer detection — a physical sensing approach. By 2018-2022 (AiPBAND), they had moved toward integrated platforms combining biosensing with machine learning and cloud computing. Their most recent engagement (oncNGS, 2020 onward) is squarely in next-generation sequencing and liquid biopsies, reflecting the broader oncology field's shift toward minimally invasive genomic diagnostics.

IFO is moving from physical biosensors toward genomic and data-driven cancer diagnostics, making them a relevant partner for precision oncology and companion diagnostics projects.

How they like to work

IFO operates exclusively as a participant or third party — they have never coordinated an H2020 project. This is typical for clinical institutions that contribute patient cohorts, clinical validation expertise, and regulatory knowledge rather than leading project management. With 52 unique partners across 12 countries from just 3 projects, they work in large, diverse consortia and are comfortable integrating into multi-partner research efforts.

Despite only three projects, IFO has collaborated with 52 distinct partners across 12 countries, indicating participation in large international consortia. Their network spans a broad European footprint rather than clustering around a single geographic region.

What sets them apart

IFO's value lies in being a major Italian cancer hospital with direct access to patient populations and clinical infrastructure for validating diagnostic technologies in real oncology settings. Unlike university labs that develop tools in isolation, IFO can provide the clinical validation step that moves diagnostics from bench to bedside. For any consortium developing cancer diagnostic devices, assays, or AI tools, IFO offers the clinical endpoint that funding agencies want to see.

Highlights from their portfolio

• ULTRAPLACAD
  Largest funded project (EUR 407K) developing ultrasensitive plasmonic biosensors for early cancer diagnosis — combining nanotechnology with clinical oncology.
• oncNGS
  A Pre-Commercial Procurement (PCP) project running until 2026, focused on making NGS diagnostics accessible and clinically validated across oncology — signals IFO's ongoing strategic direction.